Committee backs non‑opioid parity bill but adopts amendments excluding Medicaid and state plans

The Senate Health and Human Services Committee advanced Senate Bill 6, a measure designed to create coverage parity for clinically appropriate non‑opioid prescription drugs and to reduce administrative obstacles such as prior authorization and step therapy that can make non‑opioid options harder to access than opioids.

Sponsors argued SB 6 promotes patient and provider choice and aligns with CDC guidance that encourages use of non‑opioid therapies when appropriate. They described the bill as removing coverage design barriers that make opioids the path of least resistance and said several companies have non‑opioid options in the pipeline.

The hearing drew extensive testimony from patient advocates, clinicians, mental‑health and recovery organizations and chronic‑pain groups who described clinical scenarios in which safer non‑opioid medications were administratively harder to obtain. Proponents recounted stories of patients who could access opioids easily but faced delays, prior authorization or higher cost sharing for non‑opioid alternatives.

Industry witnesses urged caution. Pharmacy benefit managers and trade groups warned the committee that, currently, only a small number of branded non‑opioid options are available and that a mandate could drive premium and prescription‑drug benefit cost increases. They presented fiscal estimates projecting multi‑year premium impacts and highlighted a large price gap between certain branded non‑opioids and generic opioids.

Faced with fiscal concerns for state and Medicaid budgets, sponsors offered and the committee adopted two amendments that exclude Medicaid and state employee health plans from the bill’s requirements. Amendment L1 removed Medicaid from the mandate; amendment L4 removed state plans. Committee debate repeatedly emphasized the trade‑off: broaden access for most insured Coloradans vs. the immediate fiscal impact on state budgets.

After amendment debate and additional testimony from clinicians and advocacy groups, the committee voted to refer SB 6, as amended, to the Committee on Appropriations; the referral passed with a recorded committee vote in favor (committee reported vote 6–1).

Supporters said they will continue to seek ways to expand access and intend to revisit inclusion of state and Medicaid plans once fiscal paths are identified. Opponents urged fiscal guardrails and cost‑management language or alternative approaches.